Multiple sclerosis therapeutics market
Multiple Sclerosis Therapeutics Market, by Drug Class (Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agents and Others), by Route of Administration (Oral and Injection), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and e-Commerce), and by Region - Global Trends, and Forecast till 2025
- Feb 2018
- CMI1310
- 148 Pages
- Excel & Pdf
- Pharmaceutical
Multiple Sclerosis Therapeutics Market – Offering Long-term Disease Management
Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. The disease leads in malfunction of the nervous system to communicate, which in turn causes several signs and symptoms, including physical, mental, and psychiatric problems. Double vision, blindness in one eye, muscle weakness, trouble with sensation, or trouble with coordination are some of the other symptoms. The types of MS include relapsing-remitting MS (RRMS), primary progressive MS (PPMS), and secondary progressive MS (SPMS). RPMS is the most common type characterized by defined attacks with increasing neurological symptoms, PPMS is the rare form characterized by gradual progression of disease, whereas SPMS is commonly identified in people living with relapsed-remitting MS. The most common symptoms of the disease include partial or complete vision loss, prolonged vision loss, lack of coordination, and slurred speech.
A combination of genetic and environmental factors is responsible for the occurrence of the condition. According to a study by International Progressive Alliance, 2013, MS is two to three times more common in women than in men, suggesting that hormones play a significant role in determining susceptibility to the disease.
The global multiple sclerosis therapeutics market was valued at US$ 19.6 billion in 2016 and is expected to witness a robust CAGR of 2.5% over the forecast period (2017 - 2025).
Figure 1. Global Multiple Sclerosis Therapeutics Market (US$ Mn), by Region, 2016
Source: Coherent Market Insights (2018)
Increasing prevalence of multiple sclerosis to augment market growth
Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group 20–50 years. According to the Multiple Sclerosis Foundation, 2017, this autoimmune condition affects 2.5 million people with the global incidence of around 7 cases per 100,000 people per year. The study also states that prevalence rates varies between ethnic and geographical latitudes, ranging from 50 to 120 people per 100,000 population. North America dominates the multiple sclerosis therapeutics market owing to the high prevalence of the condition and the rising economic burden of the disease leading to the adoption of novel therapeutics. According to the Multiple Sclerosis Foundation, 2015, an estimated 400,000 people live with the disease in U.S., and about 200 new cases are diagnosed every week. According to a survey by Healthline Media, 2015, multiple sclerosis ranks second after congestive heart failure with direct and indirect health care costs ranging from US$ 8,528 to US$ 54,244 per patient per year. Higher therapy cost is restraining the growth of the multiple sclerosis therapeutics market.
Intensive R&D programs undertaken by organizations to accelerate the market growth
Various organizations such as National Institute of Neurological Disorders and Stroke, National MS Society, Parkinson’s Action Network are undertaking extensive efforts to create novel therapies for MS, contributing to be a vital factor driving the growth of global multiple sclerosis therapeutics market. For instance, the scientists at Multiple Sclerosis International Federation are undertaking research to understand, manage and treat the disease and are currently undertaking clinical trials to investigate the potential of stem cell therapies including mesenchymal stem cell (MSCs), hematopoietic stem cells (HSCs) and neural stem cells (NSCs). Also, in 2013, the Progressive MS Alliance was established to specifically research and develop more treatment options for people with the progressive forms of MS which currently has a total of 20 projects with researchers based in nine countries. Additionally, in 2015, the MS Society of Canada and the Canadian Institute of Health Research funded a new research to the University of Alberta to examine novel therapeutic strategy to reduce inflammation in the brain, a key factor contributing to the muscle disability associated with multiple sclerosis.
The major players operating in the global multiple sclerosis therapeutics market include Novartis AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bayer AG, Pfizer, Inc., Biogen Idec, Merck & Co., Inc., and AbbVie, Inc.
Table of Contents
- Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Market Trends
- Regulatory Scenario
- Reimbursement Scenario
- Alternative Therapies
- Pipeline Analysis
- Supply Chain Analysis
- PEST Analysis
- Epidemiology
- Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Beta Interferon
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Antineoplastic Agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, 2017 – 2025
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- E-Commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2025, (US$ Million)
- Global Multiple Sclerosis Therapeutics Market, By Region, 2017 – 2025, (US$ Million)
- Introduction
- Market Share Analysis, By Region, 2016 and 2025 (%)
- Y-o-Y Growth Analysis, For Regions, 2017 – 2025
- North America
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- U.S.
- Canada
- Latin America
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- Brazil
- Mexico
- Rest of Latin America
- Europe
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of APAC
- Middle East
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Drug Class, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Route of Administration, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 – 2025, (US$ Million)
- Market Size and Forecast, By Country, 2017 – 2025, (US$ Million)
- South Africa
- Central Africa
- North Africa
- Competitive Landscape
- Heat Map Analysis
- Market Share Analysis (3x3 Matrix)
- Company Profiles
- Novartis AG*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Teva Pharmaceuticals Industries Ltd.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Sanofi S.A.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Bayer AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Biogen Idec
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Merck & Co., Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- AbbVie, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Future Plans
- Analyst Views
- Section
- References
- Research Methodology
- About us and Sales Contact
*Browse 35 market data tables and 40 figures on "Multiple Sclerosis Therapeutics Market - Global forecast to 2025”.